Boston Scientific's Trading Volume Drops 45.88% to $511 Million, Ranked Third in Daily Decline

On June 17, 2025, Boston Scientific (BSX) saw a trading volume of $511 million, marking a 45.88% decrease from the previous day. The stock closed with a 0.23% increase, marking its third consecutive day of gains, with a total increase of 3.21% over the past three days.

Boston Scientific has demonstrated significant growth over the past year, with its stock price surging over 30%. This performance is largely attributed to new product launches that have bolstered sales growth and expanded profit margins. The company's revenue has shown considerable growth, with an average rate of 13.1% over the last three years, significantly outperforming the S&P 500's 5.5% increase. More recently, Boston Scientific’s revenues grew by 19.4% over the last twelve months, increasing from $15 billion to $18 billion. In its most recent quarter, quarterly revenues saw a robust 20.9% rise, reaching $4.7 billion from $3.9 billion a year ago.

Despite its strong revenue growth, Boston Scientific's valuation appears relatively expensive compared to the broader market. The company’s price-to-sales (P/S) ratio stands at 8.3, substantially higher than the S&P 500’s 3.0. Similarly, its price-to-free cash flow (P/FCF) ratio of 38.0 dwarfs the benchmark’s 20.5. Furthermore, Boston Scientific’s price-to-earnings (P/E) ratio is a significant 71.4, compared to the S&P 500’s 26.4. These figures collectively indicate that investors are paying a substantial premium for Boston Scientific’s sales, profits, and cash flow relative to the overall market.

Boston Scientific’s profit margins generally sit around the median for companies within the Trefis coverage universe. Over the last four quarters, Boston Scientific’s operating income was $3.2 billion, translating to a good operating margin of 18.5%, which is higher than the S&P 500’s 13.2%. Boston Scientific’s Operating Cash Flow (OCF) for the same period was $3.8 billion, indicating a good OCF margin of 21.7% compared to the S&P 500’s 14.9%. Boston Scientific’s Net Income for the last four quarters was $2.0 billion, yielding a moderate net income margin of 11.6%, aligning with the S&P 500’s average.

Boston Scientific’s balance sheet appears to be moderate. As of the most recent quarter, the company’s debt stood at $12 billion, against a substantial market capitalization of $147 billion. This translates to a strong Debt-to-Equity Ratio of 8.1%, which is considerably lower and more desirable than the S&P 500’s 19.9%. However, a minor concern arises from its cash position; cash and cash equivalents of $725 million represent a poor Cash-to-Assets Ratio of 1.8% when compared to total assets of $40 billion.

Boston Scientific’s stock has shown mixed performance during past market downturns, at times faring worse than the S&P 500. During the “Inflation Shock” of 2022, BSX stock experienced a 25.2% decline, aligning closely with the S&P 500’s 25.4% drop, and fully recovered by December 2022. The COVID-19 pandemic in 2020 saw a more significant impact, with BSX stock falling 43.5% compared to the S&P 500’s 33.9% decline, though it fully recovered by August 2021. The Global Financial Crisis of 2008 presented the most substantial challenge, with BSX stock plummeting 70.5% against the S&P 500’s 56.8% fall, and taking until November 2015 to fully recover.